The global market for Non-Insulin Peptide Drug was valued at US$ 55635 million in the year 2024 and is projected to reach a revised size of US$ 108788 million by 2031, growing at a CAGR of 10.4% during the forecast period.

Non-Insulin Peptide Drug Market

Non-Insulin Peptide Drugs refer to therapeutic peptide-based agents other than insulin that act by mimicking or modulating endogenous peptide hormones, ligands, or signaling pathways. They exhibit high specificity, low systemic toxicity, and targeted pharmacological actions compared to conventional small molecules. These drugs are being widely developed for indications beyond diabetes, including obesity, metabolic syndrome, autoimmune disorders, oncology, and cardiovascular diseases. With the advancement of peptide synthesis, formulation science, and delivery technologies, new administration routes—such as oral, subcutaneous, and nasal delivery—are being commercialized, driving the transition from hormone replacement therapies toward systemic disease modulation. This segment has become one of the most rapidly expanding frontiers in the global biopharmaceutical market.The average gross profit margin of this product is 70%.

The expansion of the Non-Insulin Peptide Drug market is driven by advances in precision medicine and peptide synthesis. Unmet clinical needs—particularly in metabolic disorders, obesity, and inflammatory diseases—provide vast opportunities. The commercial success of next-generation GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and PTH analogs has validated the therapeutic and safety advantages of peptide drugs in chronic disease management. Integration with AI-driven drug discovery and long-acting delivery technologies further accelerates innovation and commercialization, fueling sustained momentum in this field.

Despite their pharmacological advantages, Non-Insulin Peptide Drugs face significant hurdles including high synthesis costs, poor chemical stability, and limited oral bioavailability. Regulatory agencies are tightening standards on product consistency, delivery safety, and long-term toxicity. Market concentration around a few leading GLP-1 analogs heightens competition, requiring newcomers to pursue differentiated mechanisms or delivery platforms. Additionally, patent constraints and manufacturing costs remain key barriers to broader adoption.

The rising prevalence of obesity, metabolic disorders, and aging populations is driving steady growth in demand for Non-Insulin Peptide Drugs. Healthcare systems and pharmacies increasingly favor long-acting formulations and combination therapies that enhance patient compliance. The integration of digital health and telemedicine further enables personalized peptide treatment regimens, strengthening patient engagement and therapeutic continuity.

Upstream production of Non-Insulin Peptide Drugs relies on high-purity amino acids, solid-phase synthesis resins, coupling reagents, and sterile formulation excipients. Suppliers of specialty amino acids and protected intermediates represent the cost-dominant component of the manufacturing process. The quality of cold-chain logistics and aseptic filling technologies directly impacts drug stability. Meanwhile, the peptide-focused CMO/CDMO sector is becoming increasingly consolidated, with integrated synthesis–purification manufacturers emerging as critical partners for innovative peptide drug development.

This report aims to provide a comprehensive presentation of the global market for Non-Insulin Peptide Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Insulin Peptide Drug.

The Non-Insulin Peptide Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Non-Insulin Peptide Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, by Route of Administration and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Non-Insulin Peptide Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Non-Insulin Peptide Drug Market Report

Report Metric	Details
Report Name	Non-Insulin Peptide Drug Market
Accounted market size in year	US$ 55635 million
Forecasted market size in 2031	US$ 108788 million
CAGR	10.4%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	GLP-1 Somatostatin Analogs (octreotide, lanreotide, etc.) PTH Analogs Calcitonin & Analogs Other
Segment by Route of Administration	Ready-to-use Injection Pre-filled Syringe Lyophilized Powder for Injection
Segment by Therapeutic Indicatio	Cancer Metabolic Disorders Central Nervous System Other
Segment by Application	Hospital Retail Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie, Ipsen, Ferring, Merck, The Medicines, J & J
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Route of Administration etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Insulin Peptide Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Non-Insulin Peptide Drug Market growing?

Ans: The Non-Insulin Peptide Drug Market witnessing a CAGR of 10.4% during the forecast period 2025-2031.

What is the Non-Insulin Peptide Drug Market size in 2031?

Ans: The Non-Insulin Peptide Drug Market size in 2031 will be US$ 108788 million.

Who are the main players in the Non-Insulin Peptide Drug Market report?

Ans: The main players in the Non-Insulin Peptide Drug Market are Sanofi, Teva, Novo Nordisk, Takeda, Eli Lilly, AstraZeneca, Novartis, AbbVie, Ipsen, Ferring, Merck, The Medicines, J & J

What are the Application segmentation covered in the Non-Insulin Peptide Drug Market report?

Ans: The Applications covered in the Non-Insulin Peptide Drug Market report are Hospital, Retail Pharmacy, Other

What are the Type segmentation covered in the Non-Insulin Peptide Drug Market report?

Ans: The Types covered in the Non-Insulin Peptide Drug Market report are GLP-1, Somatostatin Analogs (octreotide, lanreotide, etc.), PTH Analogs, Calcitonin & Analogs, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Non-Insulin Peptide Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 GLP-1

1.2.3 Somatostatin Analogs (octreotide, lanreotide, etc.)

1.2.4 PTH Analogs

1.2.5 Calcitonin & Analogs

1.2.6 Other

1.3 Market by Route of Administration

1.3.1 Global Non-Insulin Peptide Drug Market Size Growth Rate by Route of Administration: 2020 VS 2024 VS 2031

1.3.2 Ready-to-use Injection

1.3.3 Pre-filled Syringe

1.3.4 Lyophilized Powder for Injection

1.4 Market by Therapeutic Indicatio

1.4.1 Global Non-Insulin Peptide Drug Market Size Growth Rate by Therapeutic Indicatio: 2020 VS 2024 VS 2031

1.4.2 Cancer

1.4.3 Metabolic Disorders

1.4.4 Central Nervous System

1.4.5 Other

1.5 Market by Application

1.5.1 Global Non-Insulin Peptide Drug Market Growth by Application: 2020 VS 2024 VS 2031

1.5.2 Hospital

1.5.3 Retail Pharmacy

1.5.4 Other

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Non-Insulin Peptide Drug Market Perspective (2020-2031)

2.2 Global Non-Insulin Peptide Drug Growth Trends by Region

2.2.1 Global Non-Insulin Peptide Drug Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Non-Insulin Peptide Drug Historic Market Size by Region (2020-2025)

2.2.3 Non-Insulin Peptide Drug Forecasted Market Size by Region (2026-2031)

2.3 Non-Insulin Peptide Drug Market Dynamics

2.3.1 Non-Insulin Peptide Drug Industry Trends

2.3.2 Non-Insulin Peptide Drug Market Drivers

2.3.3 Non-Insulin Peptide Drug Market Challenges

2.3.4 Non-Insulin Peptide Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Non-Insulin Peptide Drug Players by Revenue

3.1.1 Global Top Non-Insulin Peptide Drug Players by Revenue (2020-2025)

3.1.2 Global Non-Insulin Peptide Drug Revenue Market Share by Players (2020-2025)

3.2 Global Top Non-Insulin Peptide Drug Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Non-Insulin Peptide Drug Revenue

3.4 Global Non-Insulin Peptide Drug Market Concentration Ratio

3.4.1 Global Non-Insulin Peptide Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Peptide Drug Revenue in 2024

3.5 Global Key Players of Non-Insulin Peptide Drug Head office and Area Served

3.6 Global Key Players of Non-Insulin Peptide Drug, Product and Application

3.7 Global Key Players of Non-Insulin Peptide Drug, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Insulin Peptide Drug Breakdown Data by Type

4.1 Global Non-Insulin Peptide Drug Historic Market Size by Type (2020-2025)

4.2 Global Non-Insulin Peptide Drug Forecasted Market Size by Type (2026-2031)

5 Non-Insulin Peptide Drug Breakdown Data by Application

5.1 Global Non-Insulin Peptide Drug Historic Market Size by Application (2020-2025)

5.2 Global Non-Insulin Peptide Drug Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Non-Insulin Peptide Drug Market Size (2020-2031)

6.2 North America Non-Insulin Peptide Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Non-Insulin Peptide Drug Market Size by Country (2020-2025)

6.4 North America Non-Insulin Peptide Drug Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Non-Insulin Peptide Drug Market Size (2020-2031)

7.2 Europe Non-Insulin Peptide Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Non-Insulin Peptide Drug Market Size by Country (2020-2025)

7.4 Europe Non-Insulin Peptide Drug Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Non-Insulin Peptide Drug Market Size (2020-2031)

8.2 Asia-Pacific Non-Insulin Peptide Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Non-Insulin Peptide Drug Market Size by Region (2020-2025)

8.4 Asia-Pacific Non-Insulin Peptide Drug Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Non-Insulin Peptide Drug Market Size (2020-2031)

9.2 Latin America Non-Insulin Peptide Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Non-Insulin Peptide Drug Market Size by Country (2020-2025)

9.4 Latin America Non-Insulin Peptide Drug Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Non-Insulin Peptide Drug Market Size (2020-2031)

10.2 Middle East & Africa Non-Insulin Peptide Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Non-Insulin Peptide Drug Market Size by Country (2020-2025)

10.4 Middle East & Africa Non-Insulin Peptide Drug Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sanofi

11.1.1 Sanofi Company Details

11.1.2 Sanofi Business Overview

11.1.3 Sanofi Non-Insulin Peptide Drug Introduction

11.1.4 Sanofi Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.1.5 Sanofi Recent Development

11.2 Teva

11.2.1 Teva Company Details

11.2.2 Teva Business Overview

11.2.3 Teva Non-Insulin Peptide Drug Introduction

11.2.4 Teva Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.2.5 Teva Recent Development

11.3 Novo Nordisk

11.3.1 Novo Nordisk Company Details

11.3.2 Novo Nordisk Business Overview

11.3.3 Novo Nordisk Non-Insulin Peptide Drug Introduction

11.3.4 Novo Nordisk Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.3.5 Novo Nordisk Recent Development

11.4 Takeda

11.4.1 Takeda Company Details

11.4.2 Takeda Business Overview

11.4.3 Takeda Non-Insulin Peptide Drug Introduction

11.4.4 Takeda Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.4.5 Takeda Recent Development

11.5 Eli Lilly

11.5.1 Eli Lilly Company Details

11.5.2 Eli Lilly Business Overview

11.5.3 Eli Lilly Non-Insulin Peptide Drug Introduction

11.5.4 Eli Lilly Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.5.5 Eli Lilly Recent Development

11.6 AstraZeneca

11.6.1 AstraZeneca Company Details

11.6.2 AstraZeneca Business Overview

11.6.3 AstraZeneca Non-Insulin Peptide Drug Introduction

11.6.4 AstraZeneca Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.6.5 AstraZeneca Recent Development

11.7 Novartis

11.7.1 Novartis Company Details

11.7.2 Novartis Business Overview

11.7.3 Novartis Non-Insulin Peptide Drug Introduction

11.7.4 Novartis Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.7.5 Novartis Recent Development

11.8 AbbVie

11.8.1 AbbVie Company Details

11.8.2 AbbVie Business Overview

11.8.3 AbbVie Non-Insulin Peptide Drug Introduction

11.8.4 AbbVie Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.8.5 AbbVie Recent Development

11.9 Ipsen

11.9.1 Ipsen Company Details

11.9.2 Ipsen Business Overview

11.9.3 Ipsen Non-Insulin Peptide Drug Introduction

11.9.4 Ipsen Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.9.5 Ipsen Recent Development

11.10 Ferring

11.10.1 Ferring Company Details

11.10.2 Ferring Business Overview

11.10.3 Ferring Non-Insulin Peptide Drug Introduction

11.10.4 Ferring Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.10.5 Ferring Recent Development

11.11 Merck

11.11.1 Merck Company Details

11.11.2 Merck Business Overview

11.11.3 Merck Non-Insulin Peptide Drug Introduction

11.11.4 Merck Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.11.5 Merck Recent Development

11.12 The Medicines

11.12.1 The Medicines Company Details

11.12.2 The Medicines Business Overview

11.12.3 The Medicines Non-Insulin Peptide Drug Introduction

11.12.4 The Medicines Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.12.5 The Medicines Recent Development

11.13 J & J

11.13.1 J & J Company Details

11.13.2 J & J Business Overview

11.13.3 J & J Non-Insulin Peptide Drug Introduction

11.13.4 J & J Revenue in Non-Insulin Peptide Drug Business (2020-2025)

11.13.5 J & J Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Non-Insulin Peptide Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of GLP-1

Table 3. Key Players of Somatostatin Analogs (octreotide, lanreotide, etc.)

Table 4. Key Players of PTH Analogs

Table 5. Key Players of Calcitonin & Analogs

Table 6. Key Players of Other

Table 7. Global Non-Insulin Peptide Drug Market Size Growth Rate by Route of Administration (US$ Million): 2020 VS 2024 VS 2031

Table 8. Key Players of Ready-to-use Injection

Table 9. Key Players of Pre-filled Syringe

Table 10. Key Players of Lyophilized Powder for Injection

Table 11. Global Non-Insulin Peptide Drug Market Size Growth Rate by Therapeutic Indicatio (US$ Million): 2020 VS 2024 VS 2031

Table 12. Key Players of Cancer

Table 13. Key Players of Metabolic Disorders

Table 14. Key Players of Central Nervous System

Table 15. Key Players of Other

Table 16. Global Non-Insulin Peptide Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Non-Insulin Peptide Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 18. Global Non-Insulin Peptide Drug Market Size by Region (2020-2025) & (US$ Million)

Table 19. Global Non-Insulin Peptide Drug Market Share by Region (2020-2025)

Table 20. Global Non-Insulin Peptide Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 21. Global Non-Insulin Peptide Drug Market Share by Region (2026-2031)

Table 22. Non-Insulin Peptide Drug Market Trends

Table 23. Non-Insulin Peptide Drug Market Drivers

Table 24. Non-Insulin Peptide Drug Market Challenges

Table 25. Non-Insulin Peptide Drug Market Restraints

Table 26. Global Non-Insulin Peptide Drug Revenue by Players (2020-2025) & (US$ Million)

Table 27. Global Non-Insulin Peptide Drug Market Share by Players (2020-2025)

Table 28. Global Top Non-Insulin Peptide Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Insulin Peptide Drug as of 2024)

Table 29. Ranking of Global Top Non-Insulin Peptide Drug Companies by Revenue (US$ Million) in 2024

Table 30. Global 5 Largest Players Market Share by Non-Insulin Peptide Drug Revenue (CR5 and HHI) & (2020-2025)

Table 31. Global Key Players of Non-Insulin Peptide Drug, Headquarters and Area Served

Table 32. Global Key Players of Non-Insulin Peptide Drug, Product and Application

Table 33. Global Key Players of Non-Insulin Peptide Drug, Date of Enter into This Industry

Table 34. Mergers & Acquisitions, Expansion Plans

Table 35. Global Non-Insulin Peptide Drug Market Size by Type (2020-2025) & (US$ Million)

Table 36. Global Non-Insulin Peptide Drug Revenue Market Share by Type (2020-2025)

Table 37. Global Non-Insulin Peptide Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 38. Global Non-Insulin Peptide Drug Revenue Market Share by Type (2026-2031)

Table 39. Global Non-Insulin Peptide Drug Market Size by Application (2020-2025) & (US$ Million)

Table 40. Global Non-Insulin Peptide Drug Revenue Market Share by Application (2020-2025)

Table 41. Global Non-Insulin Peptide Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 42. Global Non-Insulin Peptide Drug Revenue Market Share by Application (2026-2031)

Table 43. North America Non-Insulin Peptide Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. North America Non-Insulin Peptide Drug Market Size by Country (2020-2025) & (US$ Million)

Table 45. North America Non-Insulin Peptide Drug Market Size by Country (2026-2031) & (US$ Million)

Table 46. Europe Non-Insulin Peptide Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 47. Europe Non-Insulin Peptide Drug Market Size by Country (2020-2025) & (US$ Million)

Table 48. Europe Non-Insulin Peptide Drug Market Size by Country (2026-2031) & (US$ Million)

Table 49. Asia-Pacific Non-Insulin Peptide Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 50. Asia-Pacific Non-Insulin Peptide Drug Market Size by Region (2020-2025) & (US$ Million)

Table 51. Asia-Pacific Non-Insulin Peptide Drug Market Size by Region (2026-2031) & (US$ Million)

Table 52. Latin America Non-Insulin Peptide Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 53. Latin America Non-Insulin Peptide Drug Market Size by Country (2020-2025) & (US$ Million)

Table 54. Latin America Non-Insulin Peptide Drug Market Size by Country (2026-2031) & (US$ Million)

Table 55. Middle East & Africa Non-Insulin Peptide Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 56. Middle East & Africa Non-Insulin Peptide Drug Market Size by Country (2020-2025) & (US$ Million)

Table 57. Middle East & Africa Non-Insulin Peptide Drug Market Size by Country (2026-2031) & (US$ Million)

Table 58. Sanofi Company Details

Table 59. Sanofi Business Overview

Table 60. Sanofi Non-Insulin Peptide Drug Product

Table 61. Sanofi Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 62. Sanofi Recent Development

Table 63. Teva Company Details

Table 64. Teva Business Overview

Table 65. Teva Non-Insulin Peptide Drug Product

Table 66. Teva Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 67. Teva Recent Development

Table 68. Novo Nordisk Company Details

Table 69. Novo Nordisk Business Overview

Table 70. Novo Nordisk Non-Insulin Peptide Drug Product

Table 71. Novo Nordisk Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 72. Novo Nordisk Recent Development

Table 73. Takeda Company Details

Table 74. Takeda Business Overview

Table 75. Takeda Non-Insulin Peptide Drug Product

Table 76. Takeda Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 77. Takeda Recent Development

Table 78. Eli Lilly Company Details

Table 79. Eli Lilly Business Overview

Table 80. Eli Lilly Non-Insulin Peptide Drug Product

Table 81. Eli Lilly Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 82. Eli Lilly Recent Development

Table 83. AstraZeneca Company Details

Table 84. AstraZeneca Business Overview

Table 85. AstraZeneca Non-Insulin Peptide Drug Product

Table 86. AstraZeneca Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 87. AstraZeneca Recent Development

Table 88. Novartis Company Details

Table 89. Novartis Business Overview

Table 90. Novartis Non-Insulin Peptide Drug Product

Table 91. Novartis Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 92. Novartis Recent Development

Table 93. AbbVie Company Details

Table 94. AbbVie Business Overview

Table 95. AbbVie Non-Insulin Peptide Drug Product

Table 96. AbbVie Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 97. AbbVie Recent Development

Table 98. Ipsen Company Details

Table 99. Ipsen Business Overview

Table 100. Ipsen Non-Insulin Peptide Drug Product

Table 101. Ipsen Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 102. Ipsen Recent Development

Table 103. Ferring Company Details

Table 104. Ferring Business Overview

Table 105. Ferring Non-Insulin Peptide Drug Product

Table 106. Ferring Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 107. Ferring Recent Development

Table 108. Merck Company Details

Table 109. Merck Business Overview

Table 110. Merck Non-Insulin Peptide Drug Product

Table 111. Merck Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 112. Merck Recent Development

Table 113. The Medicines Company Details

Table 114. The Medicines Business Overview

Table 115. The Medicines Non-Insulin Peptide Drug Product

Table 116. The Medicines Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 117. The Medicines Recent Development

Table 118. J & J Company Details

Table 119. J & J Business Overview

Table 120. J & J Non-Insulin Peptide Drug Product

Table 121. J & J Revenue in Non-Insulin Peptide Drug Business (2020-2025) & (US$ Million)

Table 122. J & J Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Non-Insulin Peptide Drug Picture

Figure 2. Global Non-Insulin Peptide Drug Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Non-Insulin Peptide Drug Market Share by Type: 2024 VS 2031

Figure 4. GLP-1 Features

Figure 5. Somatostatin Analogs (octreotide, lanreotide, etc.) Features

Figure 6. PTH Analogs Features

Figure 7. Calcitonin & Analogs Features

Figure 8. Other Features

Figure 9. Global Non-Insulin Peptide Drug Market Size Comparison by Route of Administration (2020-2031) & (US$ Million)

Figure 10. Ready-to-use Injection Features

Figure 11. Pre-filled Syringe Features

Figure 12. Lyophilized Powder for Injection Features

Figure 13. Global Non-Insulin Peptide Drug Market Size Comparison by Therapeutic Indicatio (2020-2031) & (US$ Million)

Figure 14. Cancer Features

Figure 15. Metabolic Disorders Features

Figure 16. Central Nervous System Features

Figure 17. Other Features

Figure 18. Global Non-Insulin Peptide Drug Market Size by Application (2020-2031) & (US$ Million)

Figure 19. Global Non-Insulin Peptide Drug Market Share by Application: 2024 VS 2031

Figure 20. Hospital Case Studies

Figure 21. Retail Pharmacy Case Studies

Figure 22. Other Case Studies

Figure 23. Non-Insulin Peptide Drug Report Years Considered

Figure 24. Global Non-Insulin Peptide Drug Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 25. Global Non-Insulin Peptide Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 26. Global Non-Insulin Peptide Drug Market Share by Region: 2024 VS 2031

Figure 27. Global Non-Insulin Peptide Drug Market Share by Players in 2024

Figure 28. Global Non-Insulin Peptide Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 29. The Top 10 and 5 Players Market Share by Non-Insulin Peptide Drug Revenue in 2024

Figure 30. North America Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. North America Non-Insulin Peptide Drug Market Share by Country (2020-2031)

Figure 32. United States Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Canada Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. Europe Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Europe Non-Insulin Peptide Drug Market Share by Country (2020-2031)

Figure 36. Germany Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. France Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. U.K. Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Italy Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Russia Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Ireland Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Asia-Pacific Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Asia-Pacific Non-Insulin Peptide Drug Market Share by Region (2020-2031)

Figure 44. China Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Japan Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. South Korea Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Southeast Asia Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. India Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Australia & New Zealand Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 50. Latin America Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Latin America Non-Insulin Peptide Drug Market Share by Country (2020-2031)

Figure 52. Mexico Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Brazil Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 54. Middle East & Africa Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. Middle East & Africa Non-Insulin Peptide Drug Market Share by Country (2020-2031)

Figure 56. Israel Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 57. Saudi Arabia Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 58. UAE Non-Insulin Peptide Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 59. Sanofi Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 60. Teva Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 61. Novo Nordisk Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 62. Takeda Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 63. Eli Lilly Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 64. AstraZeneca Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 65. Novartis Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 66. AbbVie Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 67. Ipsen Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 68. Ferring Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 69. Merck Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 70. The Medicines Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 71. J & J Revenue Growth Rate in Non-Insulin Peptide Drug Business (2020-2025)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions